|
EvaluatePharma
EvaluatePharma is developed by Evaluate Ltd, UK; it is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Evaluate supports life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Evaluate's global team of dedicated healthcare analysts employ rigorous methodologies to deliver strategic commercial analysis.
The Evaluate services offer value by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity
Lingmed is the exclusive partner of Evaluate for China Market
- Analysis of sales history and sales forecast of 10,000+ companies and 100,000+products on market and in pipeline
- Monthly update to track every significant data change and market event
- Detailed sales analysis by indication or by disease area
- Customized report available to be exported quickly
- Additional modules like Clinical Trial Analysis, NPV analysis, Epidemiology information, patent insights, M&A, deals& partnering opportunities, and product launch possibility analysis, etc. are also available
|
EvaluateMedTech
EvaluateMedTech provides a new standard in integrated analysis and consensus forecasts to 2022 of the medical device and diagnostic industry. It offers many features not available anywhere else. Carefully crafted by our team of economists, industry analysts and technicians, EvaluateMedTech gives you intelligence to act on. EvaluateMedTech's World Preview brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the medtech industry between now and 2022.
- Unrivaled company consensus sales forecasts on segments and products through 2022
- Company financials, company segment sales with market share and rankings
- FDA regulatory applications and approvals, Japan PMDA and EU CE Mark approvals
- Robust News Manager with advanced search and alerts
- M&A and financing activities
- Clinical trial activity
- Pipeline development
- Customize reports by preference
- Regulatory insight via Devices @ FDA data including
6 integrated databases --- easy to search and extract
the data you need:
– PMAs – 510(k)s – HDEs – BLAs – PDPs
– Identifies FDA Highlighted New Medical Technologies
|
